Literature DB >> 24362533

Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.

A Batlle-López1, M G Cortiguera1, M Rosa-Garrido2, R Blanco2, E del Cerro3, V Torrano2, S D Wagner4, M D Delgado2.   

Abstract

BCL6 is a zinc-finger transcriptional repressor, which is highly expressed in germinal centre B-cells and is essential for germinal centre formation and T-dependent antibody responses. Constitutive BCL6 expression is sufficient to produce lymphomas in mice. Deregulated expression of BCL6 due to chromosomal rearrangements, mutations of a negative autoregulatory site in the BCL6 promoter region and aberrant post-translational modifications have been detected in a number of human lymphomas. Tight lineage and temporal regulation of BCL6 is, therefore, required for normal immunity, and abnormal regulation occurs in lymphomas. CCCTC-binding factor (CTCF) is a multi-functional chromatin regulator, which has recently been shown to bind in a methylation-sensitive manner to sites within the BCL6 first intron. We demonstrate a novel CTCF-binding site in BCL6 exon1A within a potential CpG island, which is unmethylated both in cell lines and in primary lymphoma samples. CTCF binding, which was found in BCL6-expressing cell lines, correlated with the presence of histone variant H2A.Z and active histone marks, suggesting that CTCF induces chromatin modification at a transcriptionally active BCL6 locus. CTCF binding to exon1A was required to maintain BCL6 expression in germinal centre cells by avoiding BCL6-negative autoregulation. Silencing of CTCF in BCL6-expressing cells reduced BCL6 mRNA and protein expression, which is sufficient to induce B-cell terminal differentiation toward plasma cells. Moreover, lack of CTCF binding to exon1A shifts the BCL6 local chromatin from an active to a repressive state. This work demonstrates that, in contexts in which BCL6 is expressed, CTCF binding to BCL6 exon1A associates with epigenetic modifications indicative of transcriptionally open chromatin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362533     DOI: 10.1038/onc.2013.535

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

1.  Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas.

Authors:  Xing Wang; Zhiping Li; Akira Naganuma; B Hilda Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-29       Impact factor: 11.205

2.  Acetylation inactivates the transcriptional repressor BCL6.

Authors:  Oksana R Bereshchenko; Wei Gu; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2002-10-28       Impact factor: 38.330

Review 3.  Roles of BCL6 in normal and transformed germinal center B cells.

Authors:  Katia Basso; Riccardo Dalla-Favera
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

4.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation.

Authors:  B H Ye; G Cattoretti; Q Shen; J Zhang; N Hawe; R de Waard; C Leung; M Nouri-Shirazi; A Orazi; R S Chaganti; P Rothman; A M Stall; P P Pandolfi; R Dalla-Favera
Journal:  Nat Genet       Date:  1997-06       Impact factor: 38.330

5.  Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.

Authors:  Sergei Vatolin; Ziedulla Abdullaev; Svetlana D Pack; Patrick T Flanagan; Mary Custer; Dmitri I Loukinov; Elena Pugacheva; Julie A Hong; Herbert Morse; David S Schrump; John I Risinger; J Carl Barrett; Victor V Lobanenkov
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

6.  CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms.

Authors:  E M Klenova; R H Nicolas; H F Paterson; A F Carne; C M Heath; G H Goodwin; P E Neiman; V V Lobanenkov
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

7.  Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation.

Authors:  Elena M Pugacheva; Vijay Kumar Tiwari; Ziedulla Abdullaev; Alexander A Vostrov; Patrick T Flanagan; Wolfgang W Quitschke; Dmitri I Loukinov; Rolf Ohlsson; Victor V Lobanenkov
Journal:  Hum Mol Genet       Date:  2005-02-24       Impact factor: 6.150

8.  FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.

Authors:  Shanshan Duan; Lukas Cermak; Julia K Pagan; Mario Rossi; Cinzia Martinengo; Paola Francia di Celle; Bjoern Chapuy; Margaret Shipp; Roberto Chiarle; Michele Pagano
Journal:  Nature       Date:  2012-01-05       Impact factor: 49.962

9.  Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6.

Authors:  R Reljic; S D Wagner; L J Peakman; D T Fearon
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

10.  CTCFBSDB 2.0: a database for CTCF-binding sites and genome organization.

Authors:  Jesse D Ziebarth; Anindya Bhattacharya; Yan Cui
Journal:  Nucleic Acids Res       Date:  2012-11-27       Impact factor: 16.971

View more
  10 in total

1.  TET-catalyzed oxidation of intragenic 5-methylcytosine regulates CTCF-dependent alternative splicing.

Authors:  Ryan J Marina; David Sturgill; Marc A Bailly; Morgan Thenoz; Garima Varma; Maria F Prigge; Kyster K Nanan; Sanjeev Shukla; Nazmul Haque; Shalini Oberdoerffer
Journal:  EMBO J       Date:  2015-12-28       Impact factor: 11.598

Review 2.  Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders.

Authors:  Yan Bao; Xuetao Cao
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

Review 3.  Mutual interaction between BCL6 and miRNAs contributing to the pathogenesis of various cancers.

Authors:  Z Wei; W Gao; Y Wu; B Ni; Y Tian
Journal:  Clin Transl Oncol       Date:  2015-06-25       Impact factor: 3.405

4.  The epigenetic regulator CTCF modulates BCL6 in lymphoma.

Authors:  Ana Batlle-López; María G Cortiguera; M Dolores Delgado
Journal:  Oncoscience       Date:  2015-09-14

5.  Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression.

Authors:  J Y Kang; S H Song; J Yun; M S Jeon; H P Kim; S W Han; T Y Kim
Journal:  Oncogene       Date:  2015-02-23       Impact factor: 9.867

Review 6.  Anti-malarial humoral immunity: the long and short of it.

Authors:  Kai J Rogers; Rahul Vijay; Noah S Butler
Journal:  Microbes Infect       Date:  2021-03-05       Impact factor: 2.700

7.  A Network Model to Describe the Terminal Differentiation of B Cells.

Authors:  Akram Méndez; Luis Mendoza
Journal:  PLoS Comput Biol       Date:  2016-01-11       Impact factor: 4.475

8.  CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis.

Authors:  Qiuhua Lai; Qingyuan Li; Chengcheng He; Yuxin Fang; Simin Lin; Jianqun Cai; Jian Ding; Qian Zhong; Yue Zhang; Changjie Wu; Xinke Wang; Juan He; Yongfeng Liu; Qun Yan; Aimin Li; Side Liu
Journal:  Aging (Albany NY)       Date:  2020-07-20       Impact factor: 5.682

9.  Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding.

Authors:  Georgina Victoria-Acosta; Karla Vazquez-Santillan; Luis Jimenez-Hernandez; Laura Muñoz-Galindo; Vilma Maldonado; Gustavo Ulises Martinez-Ruiz; Jorge Melendez-Zajgla
Journal:  Sci Rep       Date:  2015-10-07       Impact factor: 4.379

10.  Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.

Authors:  María G Cortiguera; Lorena García-Gaipo; Simon D Wagner; Javier León; Ana Batlle-López; M Dolores Delgado
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.